Disclosures for "Lifestyle Interventions vs. Monoclonal Antibodies in Mild Cognitive Impairment and Early Alzheimer’s Disease: A Comparative Review of Randomized Controlled Trials"
-
Dr. Fotuhi has nothing to disclose.
-
Mr. Pavuluri has nothing to disclose.
-
Mr. Coen has nothing to disclose.
-
Dr. Perry has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Synaptogenix. Dr. Perry has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for SAGE. Dr. Perry has stock in Synaptogenix.
-
Dr. Moghekar has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Deluca and Weizenbaum. Dr. Moghekar has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Silver Golub and Tieteel. The institution of Dr. Moghekar has received research support from NIH. Dr. Moghekar has a non-compensated relationship as a Medical Advisory Board member with Hydrocephalus Association that is relevant to AAN interests or activities. Dr. Moghekar has a non-compensated relationship as a Medical Advisory Board member with Spinal CSF Leak Foundation that is relevant to AAN interests or activities.